Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
05.05.2026 13:00
Trading the abstract allure of AI hype for a technical implementation roadmap, Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Boston concluded with heavyweights from Sanofi, Takeda, AbbVie, Regeneron, Biogen, Eli Lilly, Novo Nordisk, J&J, and Broad Institute establishing that the industry's digital future now rests on the 'first mile' of lab data integrity.
Model N Appoints Thomas Gibbs to Board of Directors
05.05.2026 13:00
Seasoned pharmaceutical executive brings over 25 years of commercial leadership to Model N boardREDWOOD CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Model N, a leading end-to-end commercialization, revenue optimization, and compliance platform for life sciences companies, announced the appointment of Thomas Gibbs to the company’s board of directors. Gibbs has over 25 years of leadership experience across Executive Management, Marketing, Sales, Commercial Operations, and Finance at small, mid-s
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
05.05.2026 12:05
Johnson & Johnson (NYSE: JNJ) today announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 (IL-23) and tumor necrosis factor-alpha (TNF-α), in patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) that is refractory to systemic therapies.1,2 The late-breaking presentations from the DUET-UC and DUET-CD studies were among the 32 company-sponsored abstracts being presented at Digestive
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
05.05.2026 12:05
Johnson & Johnson (NYSE: JNJ) today announced results from the Phase 3 FUZION study evaluating TREMFYA® (guselkumab) in adults with active perianal fistulizing Crohn's disease (CD). At Week 24, TREMFYA demonstrated significantly higher rates of combined fistula remission, a highly stringent endpoint defined as complete external closure of draining fistulas and absence of fluid collection on MRI, compared to placebo.1 Remission in patients with this complicated manifestation remains difficult to
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
05.05.2026 11:00
SANTA CLARA, Calif., May 05, 2026--Johnson & Johnson announces results from the first clinical study of the investigational OTTAVA™ Robotic Surgical System.
CVS to drop J&J's Stelara from its main formularies
05.05.2026 09:57
CVS Health said on Tuesday itwould prefer lower-cost, interchangeable biosimilars overJohnson & Johnson's psoriasis drug Stelara in its mostcommon drug lists starting July 1. * ...
Johnson & Johnson : study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease
05.05.2026 08:07
Home/ Media Center/ Press releases / Innovative Medicine / Johnson & Johnson study shows TREMFYA® is the first...
Jim Cramer Believes Competitors Might Hurt Intuitive Surgical
03.05.2026 15:51
Intuitive Surgical, Inc. (NASDAQ:ISRG) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. A caller asked for Cramer’s thoughts on the company, and he said: Here’s the thing: Both J&J and Medtronic claim they’ve got competitors. And I am worried that one of those two is going to hit […]
Jim Cramer Shares Key Trend For Johnson & Johnson (JNJ) Shares
02.05.2026 06:08
We have recently shared Jim Cramer Made A Big Prediction About OpenAI & Discussed These 20 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer. Pharmaceutical giant Johnson & Johnson (NYSE:JNJ)’s shares are up by 47% over the past year and by 10% year-to-date. Guggenheim discussed the firm on April […]
Is Johnson & Johnson (JNJ) Still Fairly Priced After Its Strong 1-Year Share Price Run?
02.05.2026 04:28
If you are wondering whether Johnson & Johnson is still reasonably priced at around US$227.19, you are not alone, especially after such a strong run in recent years. The stock has recorded a 49.6% return over the last year and 9.6% year to date, even as the share price has eased with a 6.9% decline over the past month and a small 0.1% decline over the last week. Recently, investor attention has focused on Johnson & Johnson's position as a large global healthcare group, with ongoing headlines...
Johnson & Johnson : STELARA® Pediatric Crohn’s Disease FDA Approval J&J Statement
01.05.2026 16:21
Home/ Media Center/ Press releases / Innovative Medicine / STELARA® Pediatric Crohn's Disease FDA Approval J&J...
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
01.05.2026 15:45
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Chlorpheniramine Maleate - Global Market Insights, Competitive Landscape & Industry Forecast to 2033 Featuring Viatris, Alkem Labs, Merck & Co., Johnson & Johnson, Capellon Pharma and More
01.05.2026 13:45
The chlorpheniramine maleate market is poised for growth due to rising allergic conditions, OTC antihistamine awareness, and pharmaceutical innovationDublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Chlorpheniramine Maleate Market Insights, Competitive Landscape, and Market Forecast - 2033" has been added to ResearchAndMarkets.com's offering. The global Chlorpheniramine Maleate Market is poised for significant growth, propelled by the rise in allergic conditions, heightened awareness of over-the-co
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
30.04.2026 12:02
NEW BRUNSWICK, N.J., April 30, 2026--Johnson & Johnson (NYSE: JNJ) (the "Company") today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson’s Executive Vice President and Chief Financial Officer, Joseph J. Wolk. He succeeds Darren Snellgrove who is leaving the company to become the chief financial officer of Halozyme.
Johnson & Johnson (JNJ) Highlights Sustained Efficacy in Vivacity-MG3 Trial
30.04.2026 09:53
We recently compiled a list of the 10 Most Popular Stocks on Robinhood in 2026. Johnson & Johnson is one of the most popular stocks on Robinhood. TheFly reported on April 22 that JNJ released updated findings from its Phase 3 Vivacity-MG3 trial and ongoing extension study evaluating IMAAVY (nipocalimab-aahu) in adults with generalized myasthenia […]
Johnson & Johnson : ushers in the next wave of innovation in cancer care with more than 20 clinical and real-world studies at ASCO 2026
29.04.2026 08:38
Home/ Media Center/ Press releases / Innovative Medicine / Johnson & Johnson ushers in the next wave of...
Johnson & Johnson (JNJ) – Among the 10 Best Quality Dividend Stocks to Buy According to Reddit
28.04.2026 00:02
Johnson & Johnson (NYSE:JNJ) is included among the 10 Best Quality Dividend Stocks to Buy According to Reddit. Johnson & Johnson (NYSE:JNJ) operates across a broad part of the healthcare industry. Through its subsidiaries, it focuses on developing, manufacturing, and selling medical products. The business is organized into two main segments: Innovative Medicine and MedTech. […]
Johnson & Johnson (JNJ) – Among the 10 Best Quality Dividend Stocks to Buy According to Reddit
28.04.2026 00:02
Johnson & Johnson (NYSE:JNJ) is included among the 10 Best Quality Dividend Stocks to Buy According to Reddit. Johnson & Johnson (NYSE:JNJ) operates across a broad part of the healthcare industry. Through its subsidiaries, it focuses on developing, manufacturing, and selling medical products. The business is organized into two main segments: Innovative Medicine and MedTech. […]
J&J sees AI halving the time to generate drug development leads
27.04.2026 15:03
Johnson & Johnson is using artificial intelligence to slash by half the time it takes to generate new leads for developing drugs, the company's chief information officer said on Monday. Discovering new products outright and bringing them to market using AI is not yet possible, but J&J is using the new technology to screen the "potential universe" for promising chemical compounds or biologics, CIO Jim Swanson said at the Reuters Momentum AI event in New York. The New Jersey-based pharmaceutical and medical device company has been working toward a more-focused approach to AI, honing in on core processes like AI-enabled products, drug development and supply chain optimization.
Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock
27.04.2026 14:07
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ranks 10th on this list. Elite investors have been positioning themselves in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stock as the firm transforms from a clinical-stage biotech to a high-margin commercial royalty engine. An important reason for interest […]